RU2014105172A - Способ обнаружения олигомеров бета-амилоида в образце жидкости организма и варианты его применения - Google Patents

Способ обнаружения олигомеров бета-амилоида в образце жидкости организма и варианты его применения Download PDF

Info

Publication number
RU2014105172A
RU2014105172A RU2014105172/15A RU2014105172A RU2014105172A RU 2014105172 A RU2014105172 A RU 2014105172A RU 2014105172/15 A RU2014105172/15 A RU 2014105172/15A RU 2014105172 A RU2014105172 A RU 2014105172A RU 2014105172 A RU2014105172 A RU 2014105172A
Authority
RU
Russia
Prior art keywords
ndpoi
antibody
complex
biological sample
capture antibody
Prior art date
Application number
RU2014105172/15A
Other languages
English (en)
Russian (ru)
Inventor
Мэри СЭВИДЖ
Пол ШАФРЮ
Абигейл ВУЛФ
Александр МакКЭМПБЕЛЛ
Original Assignee
Мерк Шарп И Доум Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп И Доум Корп. filed Critical Мерк Шарп И Доум Корп.
Publication of RU2014105172A publication Critical patent/RU2014105172A/ru

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
RU2014105172/15A 2011-07-13 2012-07-09 Способ обнаружения олигомеров бета-амилоида в образце жидкости организма и варианты его применения RU2014105172A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161507332P 2011-07-13 2011-07-13
US61/507,332 2011-07-13
PCT/US2012/045886 WO2013009667A1 (en) 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof

Publications (1)

Publication Number Publication Date
RU2014105172A true RU2014105172A (ru) 2015-08-20

Family

ID=47506433

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014105172/15A RU2014105172A (ru) 2011-07-13 2012-07-09 Способ обнаружения олигомеров бета-амилоида в образце жидкости организма и варианты его применения

Country Status (13)

Country Link
US (2) US20130052670A1 (https=)
EP (2) EP2732289B1 (https=)
JP (1) JP2014521089A (https=)
KR (1) KR20140072019A (https=)
CN (1) CN103782171B (https=)
AU (1) AU2012282825B2 (https=)
BR (1) BR112014000671A2 (https=)
CA (1) CA2840976A1 (https=)
DK (1) DK2732289T3 (https=)
ES (1) ES2666840T3 (https=)
MX (1) MX2014000480A (https=)
RU (1) RU2014105172A (https=)
WO (2) WO2013009667A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2699827T3 (es) 2009-06-17 2019-02-13 Biogen Ma Inc Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
IL245703B (en) * 2013-11-20 2022-07-01 Univ Iowa Res Found Methods and compositions for treating amyloid deposits
EP3797780B1 (en) 2014-04-17 2022-09-14 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing in a subject
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
EP3341725B1 (en) * 2015-08-25 2021-08-18 Prothena Biosciences Limited Methods for detecting phosphorylated alpha-synuclein
EP3415912B1 (en) 2016-02-08 2023-03-29 Sysmex Corporation Analyte detection method and reagent kit for detecting analyte
US11198867B2 (en) 2016-06-16 2021-12-14 Ionis Pharmaceuticals, Inc. Combinations for the modulation of SMN expression
CN114026109A (zh) * 2019-07-05 2022-02-08 株式会社岛津制作所 β淀粉样蛋白的单克隆抗体、和使用该抗体的β淀粉样蛋白相关肽的测定方法
CN120505310A (zh) 2020-02-28 2025-08-19 Ionis制药公司 用于调节smn2的化合物和方法
WO2022270901A1 (ko) * 2021-06-25 2022-12-29 장재원 동적 형광 또는 x-선의 표준편차와 자기상관을 활용한 조기 진단 시스템
US20240358805A1 (en) * 2021-08-30 2024-10-31 The Brigham And Women's Hospital, Inc. Methods and materials to treat neurodegenerative disease
WO2024026413A2 (en) * 2022-07-27 2024-02-01 Durin Technologies, Inc. Early detection and monitoring of neurodegenerative diseases using a multi-disease diagnostic platform
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665024A (en) 1984-10-01 1987-05-12 Becton, Dickinson And Company Fluorescent gram stain
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6082205A (en) 1998-02-06 2000-07-04 Ohio State University System and device for determining particle characteristics
DE60043165D1 (de) 1999-08-04 2009-11-26 Univ Southern California Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
JP2008502880A (ja) * 2004-04-02 2008-01-31 メルク エンド カムパニー インコーポレーテッド アミロイド前駆体タンパク質又はβアミロイド断片に結合する物質を検出する方法及び結合化合物
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
US7811563B2 (en) * 2004-10-25 2010-10-12 Northwestern University Anti-addl antibodies and uses thereof
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
CN101291692A (zh) * 2005-10-21 2008-10-22 默克制药公司 抗addl单克隆抗体及其应用
US20090181359A1 (en) * 2007-10-25 2009-07-16 Lou Sheng C Method of performing ultra-sensitive immunoassays
CA2779565A1 (en) * 2009-11-24 2011-06-03 Probiodrug Ag Novel diagnostic method for the diagnosis of alzheimer's disease or mild cognitive impairment
WO2011151076A2 (en) * 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
EP2593475B1 (en) * 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

Also Published As

Publication number Publication date
EP2732286A1 (en) 2014-05-21
WO2013009703A3 (en) 2013-03-21
WO2013009703A2 (en) 2013-01-17
EP2732286A4 (en) 2015-02-25
AU2012282825B2 (en) 2016-05-26
ES2666840T3 (es) 2018-05-08
CN103782171B (zh) 2016-12-14
KR20140072019A (ko) 2014-06-12
EP2732289A2 (en) 2014-05-21
AU2012282825A1 (en) 2014-01-16
CA2840976A1 (en) 2013-01-17
JP2014521089A (ja) 2014-08-25
DK2732289T3 (en) 2018-05-22
BR112014000671A2 (pt) 2017-02-14
US20130052670A1 (en) 2013-02-28
US20140120037A1 (en) 2014-05-01
MX2014000480A (es) 2014-06-23
WO2013009667A1 (en) 2013-01-17
CN103782171A (zh) 2014-05-07
WO2013009703A8 (en) 2014-01-23
EP2732289B1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
RU2014105172A (ru) Способ обнаружения олигомеров бета-амилоида в образце жидкости организма и варианты его применения
JP2014521089A5 (https=)
Graves et al. Implicating endothelial cell senescence to dysfunction in the ageing and diseased brain
Biesmans et al. Systemic immune activation leads to neuroinflammation and sickness behavior in mice
Wang et al. Ferulic acid ameliorates Alzheimer’s disease-like pathology and repairs cognitive decline by preventing capillary hypofunction in APP/PS1 mice
Steen Jensen et al. Cerebrospinal fluid amyloid beta and tau concentrations are not modulated by 16 weeks of moderate-to high-intensity physical exercise in patients with Alzheimer disease
Ritzel et al. Functional and transcriptional profiling of microglial activation during the chronic phase of TBI identifies an age-related driver of poor outcome in old mice
IL305904A (en) Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
Sylvestre et al. Untargeted metabolomic analysis of plasma from relapsing-remitting multiple sclerosis patients reveals changes in metabolites associated with structural changes in brain
WO2006073682A3 (en) Diagnostic test
KR20170062478A (ko) 우울증 치료약의 선택지를 예측하는 방법
WO2015027154A3 (en) Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
BR112019024138A2 (pt) Método para determinar uma presença ou ausência em uma amostra de um primeiro agregado de proteínas mal enoveladas
JP2013543581A5 (https=)
Yang et al. Effects of chronic stress on intestinal amino acid pathways
Nyawira Maranga et al. IL‐6 is upregulated in late‐stage disease in monkeys experimentally infected with Trypanosoma brucei rhodesiense
Liu et al. Potential application of hydrogel to the diagnosis and treatment of multiple sclerosis
RU2449276C1 (ru) Способ дифференциальной клинико-лабораторной диагностики степени выраженности воспалительных изменений слизистой оболочки желудка и двенадцатиперстной кишки при хроническом гастродуодените у детей с контаминацией организма химическими веществами промышленного происхождения
Dalgėdienė et al. Activation of macrophages by oligomeric proteins of different size and origin
RU2013122853A (ru) Биомаркер для болезни альцгеймера или умеренного когнитивного расстройства
Yang et al. Xiao-Xv-Ming decoction extract ameliorates brain injury in rats with thrombotic focal ischemic stroke and understanding possible therapeutic targets using proteomics.
CN104689344B (zh) 应用于老年痴呆症的早期快速检测及其多模态成像的影像制剂
Reed et al. 70. Cortisol Response to Psychosocial Stress and Working Memory Performance in Schizophrenia
RU2628816C1 (ru) Способ дифференциальной диагностики доброкачественных, первичных и вторичных злокачественных опухолей головного мозга
Wu et al. Blood-brain barrier breakdown in traumatic brain injury: current insights and future directions

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20170417